Maraviroc intensification of stable antiviral therapy in HIV-1-infected patients with poor immune restoration: MARIMUNO-ANRS 145 study.

@article{Cuzin2012MaravirocIO,
  title={Maraviroc intensification of stable antiviral therapy in HIV-1-infected patients with poor immune restoration: MARIMUNO-ANRS 145 study.},
  author={Lise Cuzin and Selma Trabelsi and Pierre Delobel and Claudine Barbuat and J. Reynes and Clotilde Allavena and Gilles Peytavin and Jade Ghosn and Caroline Lascoux-Combe and Christina K Psomas and Pierre Corbeau and Philippe Flandre},
  journal={Journal of acquired immune deficiency syndromes},
  year={2012},
  volume={61 5},
  pages={557-64}
}
OBJECTIVE To address the ability of a 24-week Maraviroc (MVC) intensification of a stable antiretroviral therapy (cART) to significantly increase the CD4 cell count slope. METHODS Patients were eligible if they had CD4 <350 cells/mm, a CD4 slope <50 cells/mm per year, and sustained plasma HIV-RNA <50 copies/mL over the last 2 years, while receiving a stable cART. Patients harboring pure X4-using viruses by a phenotypic tropism assay were excluded. MVC was added to cART for 24 weeks, at the… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS